phrykt

Braveheart Bio, Inc. (BRVE): who owns it and who trades it

As of Nov 16, 2026, BRVE insiders reported 10 purchases worth $123M in the last 12 months. The largest buyer was Forbion Growth Opportunities Fund III Cooperatief U.A. (10% owner), with $64.8M. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Braveheart Bio

From the latest filings

Overall: more buying than selling. Insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, BRVE insiders reported $123M of open-market purchases and $0 of sales.

Purchases, 12 months
$123M
10 trades, 8 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Aug 7, 2026
Filed Aug 11, 2026

Purchases and sales by month

$123M$123MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 7, 2026Marc L Andreessen +310% ownerPurchase1.10M$18.00$19.8MForm 4
Aug 7, 2026Erez ChimovitsDirectorPurchase1.67M$18.00$30MForm 4
Aug 7, 2026Erez ChimovitsDirectorPurchase273,333$18.00$4.9MForm 4
Aug 7, 2026Forbion Growth Opportunities Fund III Cooperatief U.A. +310% ownerPurchase1.68M$18.00$30.2MForm 4
Aug 7, 2026Forbion Growth Opportunities Fund III Cooperatief U.A. +310% ownerPurchase1.92M$18.00$34.6MForm 4
Aug 7, 2026James Paul RickeyCFOPurchase27,777$18.00$500KForm 4
Aug 7, 2026Christopher ViehbacherDirectorPurchase83,333$18.00$1.5MForm 4
Aug 7, 2026David I MalekDirectorPurchase4,166$18.00$75KForm 4
Aug 7, 2026Michele A. AndersonChief Development OfficePurchase1,111$18.00$20KForm 4
Aug 7, 2026David Charles LubnerDirectorPurchase55,555$18.00$1000KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Forbion Growth Opportunities Fund III Cooperatief U.A.10% owner$64.8M–Aug 7, 2026
Erez ChimovitsDirector, 10% owner$34.9M–Aug 7, 2026
Marc L Andreessen10% owner$19.8M–Aug 7, 2026
Christopher ViehbacherDirector$1.5M–Aug 7, 2026
David Charles LubnerDirector$1000K–Aug 7, 2026
James Paul RickeyChief Financial Officer$500K–Aug 7, 2026
David I MalekDirector$75K–Aug 7, 2026
Michele A. AndersonChief Development Officer$20K–Aug 7, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BRVE short interest

Moderate short interest. 5.7% of BRVE shares are sold short: about 1 share in 17. Over the last 6 reports the number of shares short went up 508%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.15M BRVE shares were sold short, 5.7% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 262,573 shares, buying them all back would take about 19.6 trading days (days to cover).

Shares short, % of all shares

5.72%Sep 15Oct 306.17%

Days to cover

19.6Aug 14Oct 3022.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.15M5.72%+5%262,57319.6
Oct 15, 20264.91M5.45%+19%417,07911.8
Sep 30, 20264.13M4.59%+68%809,9505.1
Sep 15, 20262.46M2.73%+76%328,4157.5
Aug 31, 20261.40M–+65%249,9925.6
Aug 14, 2026847,773––650,6801.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Braveheart Bio company events

Braveheart Bio filed 4 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Nov 6, 2026AnnouncementShared information with investors. Filing
  3. Sep 8, 2026ResultsReleased financial results. Filing
  4. Aug 7, 2026RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Famous investors that hold BRVE

2 of the 50 well-known investors we track reported holding BRVE in their latest 13F filing. The largest position is Israel Englander's, worth $2.3M.

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026115,035$2.3M0.0%New
Ken Griffin · Citadel AdvisorsQ3 202651,600$1M0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named BRVE in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Forbion Growth Opportunities Fund III Cooperatief U.A.13G12.9%
Nov 16, 2026Forbion Growth Opportunities Fund III Cooperatief U.A.13G12.9%
Nov 9, 2026Jiangsu Hengrui Pharmaceuticals Co., Ltd.13G8.2%
Nov 9, 2026Jiangsu Hengrui Pharmaceuticals Co., Ltd.13G8.2%
Nov 5, 2026FMR LLC13G8.2%
Nov 5, 2026FMR LLC13G8.2%

Questions about Braveheart Bio, Inc. (BRVE) stock

Are BRVE insiders buying or selling?

In the last 12 months, BRVE insiders reported 10 open-market purchases worth $123M and no sales. The latest trade was on Aug 7, 2026. See every trade.

What is the short interest in BRVE?

As of Oct 30, 2026, 5.15M BRVE shares were sold short, 5.7% of the shares outstanding, up 5.1% from the report before. At the average daily volume of 262,573 shares, buying them all back would take about 19.6 trading days (days to cover). See the history.

Which famous investors hold BRVE?

2 of the 50 well-known investors we track reported BRVE in their latest 13F filing, including Israel Englander, Ken Griffin. The largest position is worth $2.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.